BioSpace News Archive

The global medical device packaging market is expected to witness a solid growth in the coming years of the forecast period.

China Biologic Products Holdings, Inc. declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic.

International medical imaging IT and cybersecurity company Sectra has signed a digital pathology contract with Region Västmanland in Sweden.

This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19

The acquisition supports the expansion of the Brainlab business, accelerating technology adoption and broadening the company’s reach

Nordic Nanovector ASA announces that the US Food and Drug Administration has granted Fast Track designation for investigating Betalutin® for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior systemic therapies.

ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, administered every other month, reducing the treatment burden for adults and children

AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced plans to release its financial results for the second quarter of 2020 on August 6, 2020 after the close of the financial markets.

Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse, announced today financial results for the three months ended March 31, 2020.